We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+13.63%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.76B
AUM Growth
+$122M
Cap. Flow
-$172M
Cap. Flow %
-6.22%
Top 10 Hldgs %
38.62%
Holding
217
New
37
Increased
33
Reduced
47
Closed
5

Top Buys

Rank Stock Value
1
ZTS icon
Zoetis
ZTS
+$17M
2
JNJ icon
Johnson & Johnson
JNJ
+$13.8M
3
NVO
Novo Nordisk
NVO
+$8.1M
4
ELV icon
Elevance Health
ELV
+$7.92M
5
TMO icon
Thermo Fisher Scientific
TMO
+$6.37M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$42.7M
2
PFE icon
Pfizer
PFE
+$40.8M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$30.9M
4
UNH icon
UnitedHealth
UNH
+$21M
5
LLY icon
Eli Lilly
LLY
+$17.4M

Sector Composition

Rank Sector Weight
1 Healthcare 93.74%
2 Real Estate 2.75%
3 Financials 0.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLLS
76
Cellectis
CLLS
$287M
$7.87M 0.29%
278,988
-38,962
-12% -$1.12M
WMGI
77
DELISTED
Wright Medical Group Inc
WMGI
$7.74M 0.28%
266,781
– –
GWPH
78
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$7.53M 0.27%
43,598
-27,899
-39% -$4.02M
ALKS icon
79
Alkermes
ALKS
$8.39B
$7.26M 0.26%
171,042
– –
MPT
80
Medical Properties Trust
MPT
$2.81B
$7.12M 0.26%
477,409
-381,177
-44% -$5.56M
SNN icon
81
Smith & Nephew
SNN
$13.6B
$6.88M 0.25%
185,478
+141,330
+320% +$5.1M
RMD icon
82
ResMed
RMD
$30.3B
$6.76M 0.25%
58,630
– –
DOC
83
DELISTED
PHYSICIANS REALTY TRUST
DOC
$6.59M 0.24%
391,016
– –
SHPG
84
DELISTED
Shire pic
SHPG
$6.57M 0.24%
36,216
– –
RARE icon
85
Ultragenyx Pharmaceutical
RARE
$2.56B
$5.88M 0.21%
76,958
– –
ARRY
86
DELISTED
Array Biopharma Inc
ARRY
$5.54M 0.2%
364,166
+108,110
+42% +$1.66M
VTR icon
87
Ventas
VTR
$44.7B
$5.36M 0.19%
98,496
– –
UTHR icon
88
United Therapeutics
UTHR
$26.2B
$5.28M 0.19%
41,261
– –
EPZM
89
DELISTED
Epizyme, Inc
EPZM
$5.14M 0.19%
485,325
– –
ESRX
90
DELISTED
Express Scripts Holding Company
ESRX
$5.06M 0.18%
53,250
-53,250
-50% -$4.54M
GBT
91
DELISTED
Global Blood Therapeutics, Inc.
GBT
$5.03M 0.18%
132,270
+72,880
+123% +$3.23M
MDCO
92
DELISTED
Medicines Co
MDCO
$4.96M 0.18%
165,841
-72,900
-31% -$2.75M
BHC icon
93
Bausch Health
BHC
$2.25B
$4.93M 0.18%
192,000
– –
ADAP
94
DELISTED
Adaptimmune Therapeutics
ADAP
$4.77M 0.17%
351,618
-503,850
-59% -$5.28M
THC icon
95
Tenet Healthcare
THC
$21.8B
$4.68M 0.17%
164,500
– –
ASND icon
96
Ascendis Pharma A/S
ASND
$16.5B
$4.66M 0.17%
65,714
+21,800
+50% +$1.5M
ANAB icon
97
AnaptysBio
ANAB
$1.63B
$4.58M 0.17%
+45,910
New +$3.81M
ALGN icon
98
Align Technology
ALGN
$12.4B
$4.4M 0.16%
+11,244
New +$4.15M
ARNA
99
DELISTED
Arena Pharmaceuticals Inc
ARNA
$4.32M 0.16%
93,767
– –
IONS icon
100
Ionis Pharmaceuticals
IONS
$8.81B
$4.27M 0.16%
82,838
– –
2 3
4
5 6

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2018 Portfolio in Review

As of Q3 2018, Tekla Capital Management held 217 positions worth $2.76B, up 4.6% from $2.64B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Tekla Capital Management withdrew a net $172M in Q3 2018, closing 5 positions and reducing 47 holdings. Its most notable exit was Welltower Inc., an estimated $11.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Real Estate and Financials.

Against the trend, Tekla Capital Management opened a new position in Quest Diagnostics worth $4.21M.

  • Tekla Capital Management's largest Q3 2018 buy was Quest Diagnostics: 39,000 shares worth $4.21M.
  • Tekla Capital Management added most to Zoetis in Q3 2018, an estimated $17M increase.
  • Tekla Capital Management's biggest Q3 2018 reduction was Merck, cutting an estimated $42.7M.
  • Tekla Capital Management fully exited Welltower Inc. in Q3 2018, selling an estimated $11.9M.
  • Tekla Capital Management's ten largest holdings make up 39% of its $2.76B portfolio in Q3 2018.
  • Tekla Capital Management opened 37 new positions and closed 5 in Q3 2018.
  • Tekla Capital Management's portfolio value rose 4.6% quarter-over-quarter to $2.76B.

Based on Tekla Capital Management's 13F filing for Q3 2018, filed 13 Nov 2018.